32 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Oct 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
9
Ending by 2030
Oct 2029
Next term end
14
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2032 · High confidence
Also notable
Ends Feb 2035 · High confidence
Also notable
Ends Oct 2032 · High confidence
1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- 1- Yl) Ureas as P38 Map Kinase Inhibitors
US 9,108,950
The most cited patent in this portfolio, cited by 69 later US patents, top 10% of utility patents granted in 2015 in our data. Protection runs to 2032.
Inhibitor of P38 Map Kinase
US 9,447,076
Cited by 41 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
1-Pyrazolyl-3-((4-((2-Anilinopyrimidin-4 -Yl) Oxy) NAPTHTHALEN-1 - Yl) Ureas as P38 Map Knase Inhibitors
US 9,475,796
Cited by 36 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 14 to 23, 2027 · next Jan 14
- 1 fee due Feb 18, 2027The maintenance fee for 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- 1- Yl) Ureas as P38 Map Kinase Inhibitors (US 9,108,950) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
- 1 fee due Jul 26, 2027The maintenance fee for P38MAP Kinase Inhibitors (US 9,242,960) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.
- 1 fee due Aug 16, 2027The maintenance fee for P38 Map Kinase Inhibitors (US 9,260,410) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 17, 2026
What they patent
The 5 largest of its 14 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Inhibitor of P38 Map Kinase | 5 in force | to Feb 2035 |
| 1-Pyrazolyl-3-((4-((2-Anilinopyrimidin-4 -Yl) Oxy) NAPTHTHALEN-1 - Yl) Ureas as P38 Map Knase Inhibitors | 5 in force | to Oct 2032 |
| 1-Pyrazolyl-3- (4- ((2 -Anilinopyrimidin- 4 - Yl) Oxy) Napththalen- 1- Yl) Ureas as P38 Map Kinase Inhibitors | 4 in force | to Oct 2032 |
| Pyrazolyl Ureas as Kinase Inhibitors | 3 in force | to Feb 2035 |
| Respiratory Formulations and Compounds for Use Therein | 2 in force | to Oct 2031 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,293,748 | P38 Map Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,293,771 | P38 Map Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,975,285 | P38 Map Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 9,024,041 | P38 Map Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 9,260,410 | P38 Map Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 9,771,354 | Pyrazole P38 Map Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,299,073 | P38 Map Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 9,242,960 | P38MAP Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,642,773 | P38MAP Kinase Inhibitor In force · Medium confidence | In force | Medium confidence | |
| US 10,000,471 | Pyrazole P38 Map Kinase Inhibitors In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 32: 4 patents in force now held by others · 27 patents ended · 20 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.